State Street SPDR S&P Pharmaceuticals ETF
XPH
70 hedge funds and large institutions have $129M invested in State Street SPDR S&P Pharmaceuticals ETF in 2025 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 18 increasing their positions, 24 reducing their positions, and 9 closing their positions.
27% more capital invested
Capital invested by funds: $101M → $129M (+$27.6M)
11.79% more ownership
Funds ownership: 63.55% → 75.34% (+12%)
4% less funds holding
Funds holding: 73 → 70 (-3)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
25% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 24
50% less call options, than puts
Call options by funds: $569K | Put options by funds: $1.14M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$19.6M |
| 2 |
Citigroup
New York
|
+$11.1M |
| 3 |
Goldman Sachs
New York
|
+$2.6M |
| 4 |
Rockefeller Capital Management
New York
|
+$2.53M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$5.05M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$4.48M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.75M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.05M |
| 5 |
LPL Financial
San Diego,
California
|
-$803K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Commonwealth Equity Services
Waltham,
Massachusetts
| – | -$203K | -4,715 | Closed |
|
|
CP
77
Castleview Partners
Dallas,
Texas
| – | -$10.3K | -242 | Closed |
|
|
NWM
78
Nova Wealth Management
Bonita Springs,
Florida
| – | -$2.58K | -60 | Closed |
|
|
ME
79
McIlrath & Eck
Arlington,
Washington
| – | -$1.29K | -30 | Closed |
|
80
Creative Planning
Overland Park,
Kansas
| – | -$86 | -2 | Closed |
|
XPH Hedge Fund Activity: Q1 2025 in Review
70 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q1 2025, worth a combined $129M — up 27% from $101M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of XPH and 8 opened new positions — a net loss of 1 holder — while 24 trimmed existing stakes and 18 added.
The largest buyer was Bank of America, adding an estimated $19.6M. The largest seller was Morgan Stanley, cutting an estimated $5.05M.
- 70 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q1 2025, down from 73 in Q4 2024.
- Funds reported $129M of State Street SPDR S&P Pharmaceuticals ETF stock for Q1 2025, up 27% quarter-over-quarter.
- 8 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q1 2025 and 9 closed out, a net change of -1 holder.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q1 2025 was Bank of America, an estimated $19.6M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q1 2025 was Morgan Stanley, an estimated $5.05M sold.
Based on aggregated 13F filings for Q1 2025.